EBGLYSS ® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
The positive CHMP opinion is now being reviewed by the European Commission (EC). The approval of this biologic in the European Union is expected in approximately two months and its launch in the first European country could take place soon after.
Results from the Phase 3 clinical development program showed most patients (80 percent) who responded* to treatment with lebrikizumab at Week 16 weeks maintained skin clearance and itch relief through one year of treatment with monthly maintenance dosing.
“Atopic dermatitis, commonly known as atopic eczema, can have a profound impact on the quality of life for those it affects. Lebrikizumab’s targeted mechanism of action inhibits IL-13 signaling. In clinical trials, it helped patients control their disease and maintain those results long term, over 52 weeks. Additionally, its monthly maintenance dosing regimen offers convenience and flexibility, benefiting both patients and healthcare providers. The potential inclusion of this treatment in the range of options against atopic dermatitis means a significant stride toward enhancing the quality of life of individuals struggling with this challenging skin condition” said Prof. Alan Irvine, dermatologist in Children’s Health Ireland and St. James’s Hospital, Dublin & Professor in Dermatology, Trinity College Dublin.
"The positive CHMP recommendation for EBGLYSS in moderate to severe AD represents a significant milestone in bringing a next-generation biologic therapy to people living with atopic dermatitis, providing a much needed additional treatment option. We are confident that EBGLYSS, thanks to its selective mechanism of action, proven long-term efficacy and patient friendly monthly maintenance dosing has the potential to become a first-line treatment for moderate-to-severe atopic dermatitis." said Karl Ziegelbauer, Chief Scientific Officer at Almirall.
The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.1-6 Lebrikizumab binds to IL-13 protein with high affinity and specifically inhibits its downstream signaling.7-8
The CHMP opinion is based on three pivotal Phase 3 studies† including ADvocate 1 and ADvocate 2, evaluating lebrikizumab as monotherapy, and ADhere, assessing lebrikizumab in combination with topical corticosteroids (TCS), in adult and adolescent patients with moderate-to-severe atopic dermatitis. At Week 16, more than 50 percent of patients with moderate-to-severe atopic dermatitis experienced at least 75 percent reduction in disease severity (EASI-75) when receiving lebrikizumab monotherapy in the ADvocate studies and nearly 70 percent of patients receiving lebrikizumab combined with standard-of-care TCS achieved EASI-75 in the ADhere trial.
The Phase 3 clinical development program also evaluated the safety profile of lebrikizumab. Most adverse events (AE) across the studies were mild or moderate in severity nonserious, and did not lead to treatment discontinuation. The most common adverse reactions were conjunctivitis, injection site reactions, conjunctivitis allergic and dry eye.
Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Eli Lilly and Company has exclusive rights for the development and commercialization of the product in the United States and the rest of the world, not including Europe.Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe atopic dermatitis in additional European markets, including the United Kingdom and Switzerland in 2024.
† More information about the Phase 3 studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; Adhere: EudraCT Number 2019-004300-34; NCT04250337
*Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (“clear” or “almost clear”) with at least 2-point improvement and without rescue medication use at Week 16. At Week 16, responders were re-randomized to lebrikizumab 250 mg every two weeks or four weeks or placebo for an additional 36 weeks.
About lebrikizumab and Clinical Development Program
Lebrikizumab is an investigational, monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13.7-8 The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.1-6
The lebrikizumab phase III program consists of five key global studies evaluating over 1,300 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), as well as long-term extension (ADjoin) and adolescent open label (ADore) studies.
Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patients' needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused intensely on patients' needs. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenue in 2022 was €878.5 MM.
For more information, please visit almirall.com
This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.
1 Tsoi LC, et al.. J Invest Dermatol. 2019;139(7):1480-1489.
2 Bieber T. Allergy. 2020;75:54–62
3 Napolitano M, et al, Front Med (Lausanne). 2023 Apr 18;10:1165098
4 Bernardo et al, Am J Clin Dermatol 24, 753–764 (2023).
5 Gonçalves et al, Drugs in Context 2021; 10: 2021-1-7.
6 Simpson EL, et al. J Am Acad Dermatol. 2018;78(5):863-871.e11.
7 Okragly A, et al. Dermatol Ther (Heidelb). 2023;13(7):1535-1547.
8 Ultsch M, et al. J Mol Biol. 2013;425(8):1330-1339.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media contact Almirall:
Phone: (+34) 600 430 581
Pablo Divasson del Fraile
Phone: (+34) 93 291 30 87
Phone: (+34) 659 614 173
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix To Showcase Cybersecurity Solutions at GovWare 20233.10.2023 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its Extended Threat Defense (XTD) technologies at GovWare 2023 taking place October 17-19 at Singapore’s Sands Expo and Convention Centre. Located in GovWare booth C19, Verimatrix will offer hands-on demonstrations as well as customer success stories for its portfolio of award-winning XTD cybersecurity solutions that enable mobile app developers to harness the latest protections against hackers seeking to use mobile apps and websites as tools to attack enterprises. GovWare 2023 promises yet another invigorating event where knowledge, ideas, insights and technologies will be shared among cybersecurity leaders and innovators. Under the theme “Fostering Trust Through Collaboration in the New Digital Reality,” GovWare 2023, a part of the renowned Singapore International Cyber Week (SICW), is set to deliver transformative insi
Evolve Additive Solutions Announces Strategic Partnership with alphacam to Provide STEP Parts Production in Europe3.10.2023 16:00:00 CEST | Press release
Evolve Additive Solutions, provider of industrial 3D printing solutions and inventor of the transformative Selective Thermoplastic Electrophotographic Process (STEP), announces a strategic partnership with alphacam GmbH to offer STEP-manufactured parts as a service to customers throughout Europe. STEP is a groundbreaking additive manufacturing technology that addresses the manufacturing constraints in accuracy, scalability and engineering-grade materials by other technologies in market today. alphacam will combine its deep industry expertise, vast experience in printing plastic parts, and strong customer relationships with its adoption of Evolve’s Scaled Volume Production (SVP) platform to produce and deliver fully dense, high-fidelity thermoplastic parts with near injection molding surface finish and properties. This marks the 2nd partnership of this kind introduced by Evolve as part of its mission to establish STEP production centers of excellence around the world – ultimately to inc
Axius Water acquires Triplepoint Environmental, a leader in transforming wastewater lagoons3.10.2023 15:39:00 CEST | Press release
Axius Water announced today that it has acquired Colorado-based Triplepoint Environmental, a leading supplier of wastewater lagoon systems for rural communities. Axius Water is a portfolio of businesses focused on improving the effectiveness of water and wastewater treatment for industrial and municipal customers. The acquisition of Triplepoint complements Axius Water’s established expertise in nutrient management and further expands the company’s capabilities in lagoon technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003371312/en/ Founded in 2007, Triplepoint provides high-performing, high-value lagoon solutions for industrial and municipal customers across the U.S. and Canada. Triplepoint’s innovative lagoon technologies, including its flagship Ares Aerator solution, utilize existing infrastructure to ease the financial burden of upgrades while reinventing lagoons to meet new, more stringent effluent limits. A
Economist Impact Research Finds 85% of Organizations’ Ability to Adapt Falls Short3.10.2023 15:00:00 CEST | Press release
Planview, a global leader in Portfolio and Value Stream Management, today announced the findings of a global study, “Bridging the gap: turning strategy into reality,” conducted by Economist Impact, the research arm of The Economist,and commissioned by Planview. The study uncovers common disconnects in strategy implementation leading to failures in critical digital initiatives. The findings show a stark reality: if businesses do not accelerate efforts to close the gap between strategy and action, the consequences are significant: wasted work, sunk costs, failed digital transformations, and the threat of becoming obsolete. “With economic uncertainties, market disruptions, the rapid advancement of technologies like AI, and the growing digitalization imperative impacting every industry, the pace of change and complexity of decision-making is growing exponentially. Organizations across the globe are experiencing the realities of ‘adapt, evolve, or die.’ Yet only 15% of executives are confid
Boomi Introduces Boomi GPT, Further Accelerating Integration and Automation With Conversational AI3.10.2023 15:00:00 CEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced at its Silicon Valley Boomi World Tour, Boomi GPT, the first offering available in the Boomi AI suite, bringing a simple, conversational experience to the Boomi platform. With Boomi GPT, organizations can harness the power of generative AI to integrate and automate faster than ever before, further democratizing innovation and accelerating business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003268398/en/ Boomi Introduces Boomi GPT, Further Accelerating Integration and Automation With Conversational AI (Graphic: Business Wire) In every industry, companies are under intense pressure to innovate faster and achieve their boldest business ambitions. IT organizations have made massive investments in IT modernization and digital transformation, aiming to increase operational efficiencies while winning the hearts of customers. IDC forecasts $